Drugmaker Zydus Cadila has applied to the Drugs Controller General of India (DCGI) to provide additional indications for the use of his hepatitis C drug paginated interferon alpha-2b in the treatment of COVID 19.
The company said on Monday that the application follows interim results from Phase III clinical trials. Sold under PegiHep, Pegylated Interferon Alpha-2b is being remodeled for treatment with COVID-19. It is a single dose diet.
“Interim results indicate that when administered early [the drug] Patients can be helped to recover faster and avoid complications seen in advanced stages of the disease. Phase III trials were performed on 250 patients at 20–25 centers in India and detailed results will be published in a peer-reviewed scientific journal.
Managing director Sharvil Patel said, “We are encouraged by the results of a Phase III study of pigmented interferon alpha 2b, which has confirmed the virus’s ability to reduce titanium when given earlier in the disease.”
In addition to testing Phase 2 in Mexico, the company is also trying to initiate appropriate clinical trials in the US in association with the USFDA.
Leave a Reply